<DOC>
	<DOCNO>NCT00272415</DOCNO>
	<brief_summary>This prospective , open-label , non-randomized , multicenter study adult , age eighteen ( 18 ) old , newly-diagnosed recurrent unresectable Stage III Stage IV melanoma . A maximum 18 subject enrol Stage 1 study . ( Stage 1 complete enrollment June 2006 . ) A maximum 39 subject enrol Stage 2 study .</brief_summary>
	<brief_title>A Study Intravenous INO-1001 Plus Oral Temozolomide Evaluate Tolerability , Safety , Pharmacokinetics Patients With Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Biopsy proven malignant melanoma metastasis unresectable Stage III Stage IV . Subjects recurrent melanoma unresectable also eligible Measurable indicator metastasis Age 18 year old ECOG status 02 An interval time enrollment least : ) 2 week since surgical resection ( conduct ) ; b ) 4 week since prior radiotherapy chemotherapy , c ) 6 week since chemotherapy nitrosourea Hematocrit &gt; 29 % , ANC &gt; 1500 cells/ul , platelet &gt; 100,000 cells/ul Serum creatinine within laboratory 's upper limit normal Serum AST ALT â‰¤ 1.5 x laboratory 's upper limit normal Subject sign informed consent prior subject entry Female patient pregnant breastfeeding . Women childbearing potential must negative serum urine pregnancy test within 72 hour prior administration cycle study drug regimen . Subjects childbearing potential willing able use effective method contraception , consist least onebarrier method ( e.g. , condom diaphragm ) , duration study least 3 month complete treatment . Subjects previously treat DTIC TMZ Symptomatic central nervous metastasis Concurrent severe and/or uncontrolled medical disease could compromise participation study . Confirmed diagnosis hepatitis HIV infection Any medical , psychiatric , social problem might interfere performance , completion , and/or interpretation trial Patients surgery within two week prior enrollment study , recover side effect therapy Patients unwilling comply protocol judgment Principal Investigator unable abide rule protocol Subjects receive potent CYP3A4 inhibitor inducer orally parenterally within approximately 14 day prior enrollment Subjects receive amiodarone within 30 day study drug administration History hypersensitivity reaction three ( 3 ) drug mannitol Patients receive investigational study agent within 30 day Day 1 Cycle 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>INO4136g</keyword>
	<keyword>inotek</keyword>
	<keyword>Parp</keyword>
	<keyword>Temodar</keyword>
</DOC>